HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correction Polish Translation Turkish Translation Correction (v67,p1105) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holsinger, R.M.D. Articles by Collins, S. J. Search for Related Content PubMed PubMed Citation Articles by Holsinger, R.M.D. Articles by Collins, S. J. Related Collections Prion Alzheimer's disease

CSF BACE1 activity is increased in CJD and Alzheimer disease versus other dementias

From the University of Melbourne (R.M.D.H., J.S.L., A.B., C.L.M., S.J.C.), Parkville, Mental Health Research Institute of Victoria (R.M.D.H., C.L.M., S.J.C.), Parkville, and Australian National Creutzfeldt–Jakob Disease Registry (J.S.L., A.B., C.L.M., S.J.C.), Melbourne, Victoria, Australia.

Address correspondence and reprint requests to DrD. Holsinger, School of Biomedical Sciences, University of Sydney, Lidcombe, New South Wales, 1825, Australia, e-mail: d.holsinger{at}fhs.usyd.edu.au; or Dr. S.J. Collins, Department of Pathology, University of Melbourne, Parkville, Victoria, 3010, Australia, e-mail: stevenjc{at}unimelb.edu.au

To assess the diagnostic utility of CSF BACE1 activity for discriminating Alzheimer disease (AD) from other dementias, particularly Creutzfeldt–Jakob disease (CJD), the authors studied 26 patients with sporadic CJD, 21 patients with AD, and 21 patients with various non-AD, non-CJD dementias (DCs). CSF BACE1 activity was elevated in AD in comparison with DC (p = 0.01). Unexpectedly, CSF BACE1 activity was also increased in sporadic CJD (p = 0.02).

The Australian National CJD Registry is funded by the Commonwealth Department of Health and Ageing. R.M.D.H. is supported by an Early Career Researcher Grant from the University of Melbourne. This work was also supported in part by an Australian NHMRC Program Grant (no. 208978).

Disclosure: C.L. Masters is executive director and chair of the Scientific Advisory Board of Prana Biotechnology Ltd., a company aimed at providing therapeutic intervention for age-related diseases. The other authors declare no conflicts of interest.

Received December 23, 2005. Accepted in final form April 20, 2006.

This article has been cited by other articles:

				H. Zetterberg, U. Andreasson, O. Hansson, G. Wu, S. Sankaranarayanan, M. E. Andersson, P. Buchhave, E. Londos, R. M. Umek, L. Minthon, et al. Elevated Cerebrospinal Fluid BACE1 Activity in Incipient Alzheimer Disease Arch Neurol, August 1, 2008; 65(8): 1102 - 1107. [Abstract] [Full Text] [PDF]

				Z. Zhong, M. Ewers, S. Teipel, K. Burger, A. Wallin, K. Blennow, P. He, C. McAllister, H. Hampel, and Y. Shen Levels of beta-Secretase (BACE1) in Cerebrospinal Fluid as a Predictor of Risk in Mild Cognitive Impairment Arch Gen Psychiatry, June 1, 2007; 64(6): 718 - 726. [Abstract] [Full Text] [PDF]